OBJECTIVES: To estimate WTP (€, 2006 value) per incremental quality-adjusted life-year (QALY) gained for a future health technology when compared to the current technology in the treatment of a particular disease. Secondly, WTP for incremental life-year gained (LYG), and WTP for average QALY and LY were estimated. METHODS: For the first time in the Finnish setting, CV was used to establish WTP for health benefits that do not have market prices. A postal survey including 8 diseases (1092 cases in total) with dichotomous choice (DC) type questions was carried out to clinicians (N 197) and political decision makers (N 225). Based on the answers with varying costs for health benefit, aggregate demand functions (ADF) were drawn and the mean WTP for particular benefit in particular disease was estimated as the area under ADF. As a new innovation, the potential future order of disease priority in terms of WTP was established by estimating cumulative marginal changes (CMC) in ADF. The care costs and utilities were obtained from recent Finnish literature. Discounting with 5% and 0% was done due to the life-time perspectives. RESULTS: The mean WTP per incremental QALY gained with 15D/EQ-5D utilities were the following (CMCs are in the parentheses): neurological disturbance €420,921/46,8004 (€147,653/164,168), metabolic disturbance €320,974/333,961 (€118,823/123,631), cancer €127,937/138,308 (€61,611/66,604), dementia €100,536/107,731 (€40,830/43,731), paraplegia €124,544/563,41 (€35,013/15,839), coronary heart disease €48,381/50,928 (€15,191/15,989), type 1 diabetes €107,114/548,63 (€19,989/10,238), and narcomaniac €30,859/45,106 (€7,705/14,231). WTPs for incremental LYG, average QALY and LY were lower. The difference between EQ-5D and 15D WTP exceeded 10% in paraplegia, diabetes, narcomaniacs, and neurological disease. This demonstrated that the results obtained using different utility tools differ even in the ADF-setting. CONCLUSIONS: Depending on the disease and utility tool, CV based on DCs seems to result to different ADFs and WTPs. By estimating CMCs from ADFs, potential future order for diseases is estimated.